Current status and progress of novel clinical triple therapy drugs for chronic obstructive pulmonary disease
Current guidelines recommend the use of a triple therapy regimen combining inhaled corticosteroids(ICS),long-acting β2 adrenoceptor agonists(LABA),and long-acting muscarinic antagonists(LAMA)for patients with chronic obstructive pulmonary disease(COPD)who continue to experience acute exacerbations despite dual therapy with either ICS+LABA or LABA+LAMA,if the blood eosinophil count is≥ 100 cells·μL-1.Multiple studies have shown that triple therapy effectively reduced the frequency of acute exacerbations in patients with moderate to severe COPD,improved lung function and quality of life,and demonstrated good safety.The protective effect of triple therapy against acute exacerbations was even more pronounced in patients with an eosinophil count of 300 cells·μL-1 or higher.Compared to the use of multiple inhalers for triple therapy,single-inhaler triple therapy showed significant advantages in improving the forced expiratory volume in one second in COPD patients.However,there were no significant differences between the two approaches in controlling the rate of moderate to severe acute exacerbations,reducing the scores on the St.George's Respiratory Questionnaire,or in the incidence of adverse events.The efficacy and safety of different triple therapy regimens in the treatment of COPD warrant further investigation.
NETL
NSTL
万方数据
